Someone is always saying that Insmed doesn't have enough analyst coverage to own the shares.
It's better to own the shares and then get the coverage. cannacord - 12 dollar target
Others are always saying that getting a drug to market is and always will be a long, arduous, painstakng process. They are correct of course. However, the 2012 FDASIA, complete with QUIP and Breakthrough Designation is changing that:
The best description of the pathway may have been delivered by Center for Drug Evaluation & Research Director Janet Woodcock during hearings on FDASIA: she said that the “breakthrough” designation would encourage the sponsor and the agency to call “all hands on deck” to rethink the development plan rather than plow through a traditional Phase 1-2-3 process.